Tags

Type your tag names separated by a space and hit enter

Justice in CRISPR/Cas9 Research and Clinical Applications.
AMA J Ethics. 2018 09 01; 20(9):E826-833.AJ

Abstract

CRISPR/Cas9 is a rapidly developing gene editing technology that will soon have many clinical applications. As with many other new technologies, somatic gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies by historically disenfranchised racial and ethnic minorities. We describe justice concerns related to CRISPR/Cas9, including its potential impact on historically mistreated populations through underrepresentation of minorities in genomic databases and the potential for disparate access to somatic gene therapies when they become clinically available. We then describe ongoing work that aims to address these justice concerns. We conclude by highlighting important considerations to ensure equitable access to therapies going forward, including enhancing diversity in genomic sequencing efforts, improving education and transparency, and building partnerships with underserved and socially disenfranchised communities.

Authors+Show Affiliations

A third-year resident in the Boston Combined Pediatrics Residency Program and Harvard Medical School Genetics Residency Combined Training Program in Boston.A pediatric oncologist at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an ethicist at Boston Children's Hospital, and on the teaching faculty at the Harvard Medical School Center for Bioethics in Boston.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30242813

Citation

Hildebrandt, Clara C., and Jonathan M. Marron. "Justice in CRISPR/Cas9 Research and Clinical Applications." AMA Journal of Ethics, vol. 20, no. 9, 2018, pp. E826-833.
Hildebrandt CC, Marron JM. Justice in CRISPR/Cas9 Research and Clinical Applications. AMA J Ethics. 2018;20(9):E826-833.
Hildebrandt, C. C., & Marron, J. M. (2018). Justice in CRISPR/Cas9 Research and Clinical Applications. AMA Journal of Ethics, 20(9), E826-833. https://doi.org/10.1001/amajethics.2018.826
Hildebrandt CC, Marron JM. Justice in CRISPR/Cas9 Research and Clinical Applications. AMA J Ethics. 2018 09 1;20(9):E826-833. PubMed PMID: 30242813.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Justice in CRISPR/Cas9 Research and Clinical Applications. AU - Hildebrandt,Clara C, AU - Marron,Jonathan M, Y1 - 2018/09/01/ PY - 2018/9/23/entrez PY - 2018/9/23/pubmed PY - 2020/1/15/medline SP - E826 EP - 833 JF - AMA journal of ethics JO - AMA J Ethics VL - 20 IS - 9 N2 - CRISPR/Cas9 is a rapidly developing gene editing technology that will soon have many clinical applications. As with many other new technologies, somatic gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies by historically disenfranchised racial and ethnic minorities. We describe justice concerns related to CRISPR/Cas9, including its potential impact on historically mistreated populations through underrepresentation of minorities in genomic databases and the potential for disparate access to somatic gene therapies when they become clinically available. We then describe ongoing work that aims to address these justice concerns. We conclude by highlighting important considerations to ensure equitable access to therapies going forward, including enhancing diversity in genomic sequencing efforts, improving education and transparency, and building partnerships with underserved and socially disenfranchised communities. SN - 2376-6980 UR - https://www.unboundmedicine.com/medline/citation/30242813/Justice_in_CRISPR/Cas9_Research_and_Clinical_Applications_ L2 - https://journalofethics.ama-assn.org/article/justice-crisprcas9-research-and-clinical-applications/2018-09 DB - PRIME DP - Unbound Medicine ER -